A Study Assessing KB407 for the Treatment of Cystic Fibrosis
← catalyst calendarNCT05504837 · readout ≤ 134 d
Sponsored by Krystal Biotech, Inc. (industry) · KRYS — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
20estimated
Sites
6
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-06-30 | actual | When the study began enrolling |
| Primary completion | Dec 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2022-08-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Cystic Fibrosis
Intervention
- Biological: KB407 (Nebulization)
Primary outcome
what the primary-completion date above is the date OFTo evaluate safety and tolerability of KB407 based upon assessment of adverse events (frequency, severity, relatedness), and changes from baseline in physical examinations, vital signs, ECG, and clinical laboratory test results
measured 6 months
Permalink · KRYS's whole pipeline · Catalyst calendar · Every registered study · What changed